Mount Sinai Health System Partners With Contessa Health to Expand Hospital-Level Care at Home Program
The Mount Sinai Health System announced today that it has partnered with Contessa Health, an innovative health care company that manages acute-care services at home through prospective bundled payment arrangements, to extend Mount Sinai’s existing hospital-level care at home program, known as …
Technology from a Mount Sinai Startup (Cardea Sciences) That Will Improve Outcomes for Cardiac Patients Wins the NYC Life Science Innovation Showcase
July 18, 2017 – Technology for identifying at-risk atrial fibrillation (AFib) patients was chosen as the winner of the inaugural Alexandria LaunchLabs Scholarship Award, which recognizes excellence in health care technology, entrepreneurship and business competencies. The technology, developed by a Mount Sinai …
Breathing in a New Gene Therapy to Treat Pulmonary Hypertension
June 12, 2017- Mount Sinai has partnered with Theragene Pharmaceuticals, Inc. to advance a novel airway-delivered gene therapy for treating pulmonary hypertension (PH), a form of high blood pressure in blood vessels in the lungs that is linked to heart failure. If …
Mount Sinai, Pfizer Renew Research Collaboration, Building on Strong Foundation
June 28, 2017 – The Icahn School of Medicine at Mount Sinai and Pfizer Inc.’s Centers for Therapeutic Innovation (CTI) recently announced the renewal of an agreement designed to identify and advance new drug candidates linked to major diseases, such as cancer, rheumatoid …
Treating Depression with Software: Technology from Mount Sinai Steps into the Digital Healthcare Universe
June 7, 2017 – A treatment for depression using Emotional Faces Memory Task (EFMT), a technology originally developed by two Mount Sinai researchers, resulted in a significantly greater reduction of major depressive disorder (MDD) symptoms compared to a control group, according to initial …
Engineering New Anti-Cancer Drugs from Old Medicines
May 25, 2017 – An interdisciplinary collaboration including 45 researchers has discovered a new class of drug candidates that activates the tumor suppressor protein PP2A. These new compounds have been shown to inhibit the growth of lung cancer tumors in mice, and have …
Four NCI Cancer Centers Announce Landmark Research Consortium and Collaborations with Celgene
June 22, 2016 – Today, The Abramson Cancer Center at the University of Pennsylvania, The Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, and The Tisch Cancer Institute at the Icahn …
Mount Sinai and Galmed Pharmaceuticals to Collaborate in an Investigator Initiated Phase IIa Trial to Evaluate the Effect of AramcholTM in Combination with Vitamin D for the Treatment of Patients with Fibrotic Nonalcoholic Fatty Liver Disease
May 3, 2016 – Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) (“Galmed” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of liver diseases, announced today that it has signed an investigator initiated clinical trial …
Takeda Launches Multi-Year Research Partnership with Leading Inflammatory Bowel Disease Institutions
March 31, 2016 – Takeda Pharmaceuticals U.S.A., Inc. (“Takeda”), today announced a multi-year research partnership with two world leading academic centers with a proven long-term commitment to inflammatory bowel disease (IBD) research and care. The partnership, with the University of Chicago and the …
Dual Therapeutics Announces Oncology Strategic Collaboration with Bristol-Myers Squibb
January 8, 2016 – Dual Therapeutics, LLC (“Dual Therapeutics”) today announced a strategic collaboration with Bristol-Myers Squibb (NYSE: BMY) to advance small molecule compounds for the treatment of cancer and other diseases. Dual Therapeutics’ small-molecule modulators simultaneously block multiple cancer promoting pathways, …